Climb Bio, Inc.
CLYMClimb Bio is a clinical-stage biotechnology company focused on developing novel therapeutics for patients with immune-mediated diseases.
Earnings
Next report
Aug 11, 2026 (In 1 week)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Climb Bio is a clinical-stage biotechnology company focused on developing novel therapeutics for patients with immune-mediated diseases. The company strategically acquires and in-licenses product candidates with clear biological rationales to address significant unmet needs in nephrology and systemic autoimmune disorders. Its core value proposition lies in advancing next-generation monoclonal antibodies that target B-cell pathways to achieve deep and durable disease modification.
Climb Bio is a clinical-stage developer positioning its candidates as potential best-in-class alternatives to existing B-cell therapies like rituximab and emerging CAR-T approaches.
Questions, answered.
- What is Climb Bio, Inc.'s market cap?
- Climb Bio, Inc. (CLYM) has a market capitalization of $732.4M and trades on XNAS.
- Who are Climb Bio, Inc.'s competitors?
- Climb Bio, Inc.'s key competitors include Amgen Inc., Vera Therapeutics, Inc., Bristol Myers Squibb Company, and others. These companies compete in similar markets and product categories.
- Who does Climb Bio, Inc. partner with?
- Climb Bio, Inc.'s notable partners include Mabworks, Acelyrin, Inc., Cancer Research Horizons, and others.
- What subsidiaries does Climb Bio, Inc. have?
- Climb Bio, Inc.'s subsidiaries include Tenet Medicines, Inc..
- Where is Climb Bio, Inc. headquartered?
- Climb Bio, Inc. is headquartered in United States of America and employs approximately 11 people. It has been publicly traded since 2021.